Literature DB >> 27506740

Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis.

Xi Xia1, Qimei Luo1, Bin Li1, Zhenchuan Lin1, Xueqing Yu1, Fengxian Huang2.   

Abstract

BACKGROUND: Studies have shown inconsistent results about the association between serum uric acid levels and mortality in patients with chronic kidney disease (CKD).
METHODS: A systematic literature search in MEDLINE, Web of Science and bibliographies of retrieved articles was performed to identify studies investigating the association between serum uric acid and mortality in patients with CKD. Pooled hazard ratios (HR) and corresponding 95% confidence intervals (CIs) were calculated using random-effects models.
RESULTS: A total of 24 studies with 25,453 patients with CKD were included. By meta-analysis, patients with the highest serum uric acid level were associated with a significantly higher risk for mortality (14 studies; HR, 1.52; 95% CI, 1.33-1.73) compared with patients with the lowest serum uric acid level. For dose-response analysis, a linear relationship (8 studies; Pfor non-linearity=0.14) between serum uric acid levels and risk of mortality was found. Overall, an increase of 1mg/dl in serum uric acid level was associated with an 8% increased risk of mortality (21 studies; HR, 1.08; 95% CI, 1.04-1.11).
CONCLUSIONS: Elevated serum uric acid levels are significantly associated with risk of mortality in patients with CKD. Further randomized controlled trials should attempt to determine whether it improves survival to target serum uric acid in patients with CKD.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Meta-analysis; Mortality; Serum uric acid

Mesh:

Substances:

Year:  2016        PMID: 27506740     DOI: 10.1016/j.metabol.2016.05.009

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

Review 1.  Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.

Authors:  Allison Guttmann; Svetlana Krasnokutsky; Michael H Pillinger; Adey Berhanu
Journal:  Ther Adv Drug Saf       Date:  2017-09-13

Review 2.  Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review.

Authors:  Usama A A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2016-12-03       Impact factor: 10.479

Review 3.  Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies.

Authors:  Xue Li; Xiangrui Meng; Maria Timofeeva; Ioanna Tzoulaki; Konstantinos K Tsilidis; John PA Ioannidis; Harry Campbell; Evropi Theodoratou
Journal:  BMJ       Date:  2017-06-07

4.  Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.

Authors:  Atsushi Tanaka; Tsukasa Nakamura; Eiichi Sato; Koichi Node
Journal:  Drugs R D       Date:  2017-03

Review 5.  Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Authors:  Raymond Vanholder; Anneleen Pletinck; Eva Schepers; Griet Glorieux
Journal:  Toxins (Basel)       Date:  2018-01-08       Impact factor: 4.546

6.  Patients With Drug-Naive Bipolar Disorder in Remission After 8 Weeks of Treatment Had Decreased Serum Uric Acid Concentrations.

Authors:  Jing-Xu Chen; Li-Gang Zhang; Ke-Zhi Liu; Hong-Mei Chen; Shuang-Jiang Zhou; Ning Wang; Yun-Long Tan; Shao-Li Wang; Alison Jones; Fu-De Yang; Xu-Feng Huang
Journal:  Front Psychiatry       Date:  2019-10-31       Impact factor: 4.157

7.  Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage.

Authors:  Fernando E García-Arroyo; Guillermo Gonzaga; Itzel Muñoz-Jiménez; Mónica G Blas-Marron; Octaviano Silverio; Edilia Tapia; Virgilia Soto; Natarajan Ranganathan; Pari Ranganathan; Usha Vyas; Anthony Irvin; Diana Ir; Charles E Robertson; Daniel N Frank; Richard J Johnson; L Gabriela Sánchez-Lozada
Journal:  PLoS One       Date:  2018-08-24       Impact factor: 3.240

Review 8.  Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.

Authors:  Jan T Kielstein; Roberto Pontremoli; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2020-10-31       Impact factor: 5.369

9.  The Effects of Cardiometabolic Factors on the Association Between Serum Uric Acid and Chronic Kidney Disease in Chinese Middle-Aged and Older Population: A Mediation Analysis.

Authors:  Lu Xu; Hang Sun; Lili Liu; Siyan Zhan; Shengfeng Wang; Xiaozhen Lv; Yongfeng Song
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

10.  Effect and Mechanism of ShiZhiFang on Uric Acid Metabolism in Hyperuricemic Rats.

Authors:  Yansheng Wu; Yixing Wang; Jiaoying Ou; Qiang Wan; Liqiang Shi; Yingqiao Li; Fei He; Huiling Wang; Liqun He; Jiandong Gao
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-25       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.